mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2019-1-19-25mrj-881Research ArticleКЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИCLINICAL GUIDELINESМеждународные рекомендации по лечению АНЦА-ассоциированных системных васкулитовInternational guidelines for the management ofANCA-associated systemic vasculitidesБекетоваТ. В.BeketovaT. V.

Татьяна Валентиновна Бекетова

115522, Москва, Каширское шоссе, 34А

Tatiana Valentinovna Beketova

34A, Kashirskoe Shosse, Moscow 115522

tvbek22@rambler.ruФГБНУ Научно-исследовательский институт ревматологии им. В.А. НасоновойРоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation2019260320191311925Copyright © Бекетова Т.В., 20192019Бекетова Т.В.Beketova T.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/881

Статья посвящена международным рекомендациям по лечению системных васкулитов (СВ), ассоциированных с антинейтрофиль-ными цитоплазматическими антителами (АНЦА, АНЦА-СВ), представляющих собой группу тяжелых жизнеугрожающих иммуновоспалительных заболеваний. К этой группе относятся гранулематоз с полиангиитом Вегенера, микроскопический полиангиит, эозинофильный гранулематоз с полиангиитом Черджа—Строс. АНЦА-СВ являются одной из важнейших проблем практической ревматологии. Опубликованные в 2016 г. международной группой экспертов рекомендации по лечению АНЦА-СВ, в которых обобщены современные научные достижения и международный клинический опыт, до настоящего времени остаются основополагающими.

The paper deals with international guidelines for the management of antineutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitides (SVs) that are a group of severe life-threatening immune-mediated diseases. This group includes granulomatosis with polyangiitis (Wegener's granulomatosis), microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis (Churg-Strauss). ANCA-associated SVs (ANCA-SVs) are an important problem of practical rheumatology. The guidelines for the management of ANCA-SV, which were published by the International Group of Experts, which summarize modern scientific achievements and international clinical experience, currently remain the basis for treatment of these diseases.

антинейтрофильные цитоплазматические антителасистемные васкулитыгранулематоз с полиангиитоммикроскопический полиангиитэозинофильный гранулематоз с полиангиитомритуксимабantineutrophil cytoplasmic antibodiessystemic vasculitidesgranulomatosis with polyangiitismicroscopic polyangiitiseosinophilic granulomatosis with polyangiitisrituximabReferencesLuqmani RA. Treat-to-target in vasculitis: is this a sensible approach? Clin Exp Rheumatol. 2012 Jul-Aug;30(4 Suppl 73): S149-53. Epub 2012 Oct 16.Luqmani RA. Treat-to-target in vasculitis: is this a sensible approach? Clin Exp Rheumatol. 2012 Jul-Aug;30(4 Suppl 73): S149-53. Epub 2012 Oct 16.Stone JH, Merkel PA, Spiera R, et al; RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010 Jul 15;363(3): 221-32. doi: 10.1056/NEJMoa0909905.Stone JH, Merkel PA, Spiera R, et al; RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010 Jul 15;363(3): 221-32. doi: 10.1056/NEJMoa0909905.Jones RB, Tervaert JW, Hauser T, et al; European Vasculitis Study group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010 Jul 15; 363(3):211-20. doi: 10.1056/NEJMoa0909169.Jones RB, Tervaert JW, Hauser T, et al; European Vasculitis Study group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010 Jul 15; 363(3):211-20. doi: 10.1056/NEJMoa0909169.Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016 Sep;75(9): 1583-94. doi: 10.1136/annrheumdis-2016209133. Epub 2016 Jun 23.Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016 Sep;75(9): 1583-94. doi: 10.1136/annrheumdis-2016209133. Epub 2016 Jun 23.Ntatsaki E, Carruthers D, Chakravarty K, et al; BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology (Oxford). 2014 Dec;53(12):2306-9. doi: 10.1093/rheumatology/ket445. Epub 2014 Apr 11.Ntatsaki E, Carruthers D, Chakravarty K, et al; BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology (Oxford). 2014 Dec;53(12):2306-9. doi: 10.1093/rheumatology/ket445. Epub 2014 Apr 11.Guerry MJ, Brogan P, Bruce IN, et al. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford). 2012 Apr;51(4):634-43. doi: 10.1093/rheumatology/ker150. Epub 2011 May 25.Guerry MJ, Brogan P, Bruce IN, et al. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford). 2012 Apr;51(4):634-43. doi: 10.1093/rheumatology/ker150. Epub 2011 May 25.Groh M, Pagnoux C, Baldini C, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med. 2015 Sep; 26(7):545-53. doi: 10.1016/j.ejim.2015.04.022.Groh M, Pagnoux C, Baldini C, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med. 2015 Sep; 26(7):545-53. doi: 10.1016/j.ejim.2015.04.022.Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013 Jan;65(1): 1-11. doi: 10.1002/art.37715.Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013 Jan;65(1): 1-11. doi: 10.1002/art.37715.Sada KE, Yamamura M, Harigai M, et al; Research Committee on Intractable Vasculitides, the Ministry of Health, Labour and Welfare of Japan. Different responses to treatment across classified diseases and severities in Japanese patients with microscopic polyangiitis and granulomatosis with polyangiitis: a nationwide prospective inception cohort study. Arthritis Res Ther. 2015 Nov 2; 17:305. doi: 10.1186/s13075-015-0815-y.Sada KE, Yamamura M, Harigai M, et al; Research Committee on Intractable Vasculitides, the Ministry of Health, Labour and Welfare of Japan. Different responses to treatment across classified diseases and severities in Japanese patients with microscopic polyangiitis and granulomatosis with polyangiitis: a nationwide prospective inception cohort study. Arthritis Res Ther. 2015 Nov 2; 17:305. doi: 10.1186/s13075-015-0815-y.McGregor JG, Hogan SL, Hu Y, et al. Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease. Clin J Am Soc Nephrol. 2012 Feb;7(2): 240-7. doi: 10.2215/CJN.05610611.McGregor JG, Hogan SL, Hu Y, et al. Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease. Clin J Am Soc Nephrol. 2012 Feb;7(2): 240-7. doi: 10.2215/CJN.05610611.Pagnoux C, Quemeneur T, Ninet J, et al; French Vasculitis Study Group. Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamidebased induction therapy. Arthritis Rheumatol. 2015 Apr;67(4):1117-27. doi: 10.1002/art.39011.Pagnoux C, Quemeneur T, Ninet J, et al; French Vasculitis Study Group. Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamidebased induction therapy. Arthritis Rheumatol. 2015 Apr;67(4):1117-27. doi: 10.1002/art.39011.Robson J, Doll H, Suppiah R, et al. Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. Rheumatology (Oxford). 2015 Mar;54(3): 471-81. doi: 10.1093/rheumatology/keu366.Robson J, Doll H, Suppiah R, et al. Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. Rheumatology (Oxford). 2015 Mar;54(3): 471-81. doi: 10.1093/rheumatology/keu366.Silva-Fernandez L, Loza E, Martinez-Taboada VM, et al; Systemic Autoimmune Diseases Study Group of the Spanish Society for Rheumatology (EAS-SER). Biological therapy for systemic vasculitis: a systematic review. Semin Arthritis Rheum. 2014 Feb;43(4):542-57. doi: 10.1016/j.semarthrit.2013.07.010. Epub 2013 Aug 24.Silva-Fernandez L, Loza E, Martinez-Taboada VM, et al; Systemic Autoimmune Diseases Study Group of the Spanish Society for Rheumatology (EAS-SER). Biological therapy for systemic vasculitis: a systematic review. Semin Arthritis Rheum. 2014 Feb;43(4):542-57. doi: 10.1016/j.semarthrit.2013.07.010. Epub 2013 Aug 24.Holle JU, Voigt C, Both M, et al. Orbital masses in granulomatosis with polyangiitis are associated with a refractory course and a high burden of local damage. Rheumatology (Oxford). 2013 May;52(5):875-82. doi: 10.1093/rheumatology/kes382. Epub 2013 Jan 4.Holle JU, Voigt C, Both M, et al. Orbital masses in granulomatosis with polyangiitis are associated with a refractory course and a high burden of local damage. Rheumatology (Oxford). 2013 May;52(5):875-82. doi: 10.1093/rheumatology/kes382. Epub 2013 Jan 4.Pullerits R, Ljevak M, Vikgren J, et al. Off-trial evaluation of the B cell-targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: long-term follow-up from a single centre. Scand J Immunol. 2012 Oct; 76(4):411-20. doi: 10.1111/j.1365-3083.2012.02747.x.Pullerits R, Ljevak M, Vikgren J, et al. Off-trial evaluation of the B cell-targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: long-term follow-up from a single centre. Scand J Immunol. 2012 Oct; 76(4):411-20. doi: 10.1111/j.1365-3083.2012.02747.x.D∅nvik KK, Omdal R. Churg-Strausssyndrome successfully treated with rituximab. Rheumatol Int. 2011 Jan;31(1):89-91. doi: 10.1007/s00296-009-1146-6. Epub 2009 Sep 30.D∅nvik KK, Omdal R. Churg-Strausssyndrome successfully treated with rituximab. Rheumatol Int. 2011 Jan;31(1):89-91. doi: 10.1007/s00296-009-1146-6. Epub 2009 Sep 30.Cartin-Ceba R, Keogh KA, Specks U,et al. Rituximab for the treatment of ChurgStrauss syndrome with renal involvement. Nephrol Dial Transplant. 2011 Sep;26(9): 2865-71. doi: 10.1093/ndt/gfq852. Epub 2011 Feb 16.Cartin-Ceba R, Keogh KA, Specks U,et al. Rituximab for the treatment of ChurgStrauss syndrome with renal involvement. Nephrol Dial Transplant. 2011 Sep;26(9): 2865-71. doi: 10.1093/ndt/gfq852. Epub 2011 Feb 16.Munoz SA, Gandino IJ, Orden AO, Allievi A. Rituximab in the treatment of eosinophilic granulomatosis with polyangiitis. Reumatol Clin. 2015 May-Jun;11(3):165-9. doi: 10.1016/j.reuma.2014.08.005. Epub 2014 Dec 15.Munoz SA, Gandino IJ, Orden AO, Allievi A. Rituximab in the treatment of eosinophilic granulomatosis with polyangiitis. Reumatol Clin. 2015 May-Jun;11(3):165-9. doi: 10.1016/j.reuma.2014.08.005. Epub 2014 Dec 15.Mohammad AJ, Hot A, Arndt F, et al. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Ann Rheum Dis. 2016 Feb; 75(2):396-401. doi: 10.1136/annrheumdis-2014-206095. Epub 2014 Dec 2.Mohammad AJ, Hot A, Arndt F, et al. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Ann Rheum Dis. 2016 Feb; 75(2):396-401. doi: 10.1136/annrheumdis-2014-206095. Epub 2014 Dec 2.Aguirre-Valencia D, Posso-Osorio I, Bravo JC, et al. Sequential rituximab and omalizumab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Clin Rheumatol. 2017 Sep;36(9):2159-2162. doi: 10.1007/s10067-017-3780-9. Epub 2017 Jul 31.Aguirre-Valencia D, Posso-Osorio I, Bravo JC, et al. Sequential rituximab and omalizumab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Clin Rheumatol. 2017 Sep;36(9):2159-2162. doi: 10.1007/s10067-017-3780-9. Epub 2017 Jul 31.Tesfa D, Ajeganova S, Ha gglund H, et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum. 2011 Aug;63(8):2209-14. doi: 10.1002/art.30427.Tesfa D, Ajeganova S, Ha gglund H, et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum. 2011 Aug;63(8):2209-14. doi: 10.1002/art.30427.Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: A data-driven review. Arthritis Rheum. 2010 Jan;62(1):9-21. doi: 10.1002/art.25061.Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: A data-driven review. Arthritis Rheum. 2010 Jan;62(1):9-21. doi: 10.1002/art.25061.Klemmer PJ, Chalermskulrat W, Reif MS, et al. Plasmapheresis Therapy for Diffuse Alveolar Hemorrhage in Patients with Small-Vessel Vasculitis. Am J Kidney Dis. 2003 Dec; 42(6):1149-53. doi:10.1053/j.ajkd.2003.08.015Klemmer PJ, Chalermskulrat W, Reif MS, et al. Plasmapheresis Therapy for Diffuse Alveolar Hemorrhage in Patients with Small-Vessel Vasculitis. Am J Kidney Dis. 2003 Dec; 42(6):1149-53. doi:10.1053/j.ajkd.2003.08.015Levy JB, Hammad T, Coulthart A, et al. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int. 2004 Oct;66(4):1535-40. doi:10.1111/j.1523-1755.2004.00917.xLevy JB, Hammad T, Coulthart A, et al. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int. 2004 Oct;66(4):1535-40. doi:10.1111/j.1523-1755.2004.00917.xDe Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005 Aug;52(8):2461-9. doi:10.1002/art.21142De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005 Aug;52(8):2461-9. doi:10.1002/art.21142Langford CA, Talar-Williams C, Sneller MC. Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis. Long-term renal outcome in patients with lomerulonephritis. Arthritis Rheum. 2000 Aug; 43(8):1836-40. doi:10.1002/1529-0131(200008)43:8<1836::AID-ANR20>3.0.CO;2-RLangford CA, Talar-Williams C, Sneller MC. Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis. Long-term renal outcome in patients with lomerulonephritis. Arthritis Rheum. 2000 Aug; 43(8):1836-40. doi:10.1002/1529-0131(200008)43:8<1836::AID-ANR20>3.0.CO;2-RMetzler C, Hellmich B, Gause A, et al. Churg Strauss syndrome-successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment. Clin Exp Rheumatol. 2004;22(6 Suppl 36): S52-61.Metzler C, Hellmich B, Gause A, et al. Churg Strauss syndrome-successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment. Clin Exp Rheumatol. 2004;22(6 Suppl 36): S52-61.Miloslavsky EM, Specks U, Merkel PA, et al. Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids. Arthritis Rheumatol. 2015 Jun;67(6):1629-36. doi: 10.1002/art.39104.Miloslavsky EM, Specks U, Merkel PA, et al. Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids. Arthritis Rheumatol. 2015 Jun;67(6):1629-36. doi: 10.1002/art.39104.Fortin PM, Tejani AM, Bassett K, et al. Intravenous immunoglobulin as adjuvant therapy for Wegener's granulomatosis. Cochrane Database Syst Rev 2013;1: CD007057. doi:10.1002/14651858.CD007057.pub3Fortin PM, Tejani AM, Bassett K, et al. Intravenous immunoglobulin as adjuvant therapy for Wegener's granulomatosis. Cochrane Database Syst Rev 2013;1: CD007057. doi:10.1002/14651858.CD007057.pub3Koike H, Akiyama K, Saito T, et al. Research Group for IVIg for EGPA/CSS in Japan. Intravenous immunoglobulin for chronic residual peripheral neuropathy in eosinophilic granulomatosis with polyangiitis (Churg—Strauss syndrome): a multicenter, double-blind trial. JNeurol. 2015 Mar;262(3): 752-9. doi: 10.1007/s00415-014-7618-y. Epub 2015 Jan 11.Koike H, Akiyama K, Saito T, et al. Research Group for IVIg for EGPA/CSS in Japan. Intravenous immunoglobulin for chronic residual peripheral neuropathy in eosinophilic granulomatosis with polyangiitis (Churg—Strauss syndrome): a multicenter, double-blind trial. JNeurol. 2015 Mar;262(3): 752-9. doi: 10.1007/s00415-014-7618-y. Epub 2015 Jan 11.Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim-sulfamethoxazole (Co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. N Engl J Med. 1996 Jul 4;335(1):16-20. doi:10.1056/NEJM199607043350103Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim-sulfamethoxazole (Co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. N Engl J Med. 1996 Jul 4;335(1):16-20. doi:10.1056/NEJM199607043350103Katsuyama T, Saito K, Kubo S, et al. Prophylaxis for Pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study. Arthritis Res Ther. 2014 Feb 5; 16(1):R43. doi: 10.1186/ar4472.Katsuyama T, Saito K, Kubo S, et al. Prophylaxis for Pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study. Arthritis Res Ther. 2014 Feb 5; 16(1):R43. doi: 10.1186/ar4472.Jayne DRW, Bruchfeld AN, Harper L, et al. Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis. J Am Soc Nephrol. 2017 Sep;28(9): 2756-2767. doi: 10.1681/ASN.2016111179. Epub 2017 Apr 11.Jayne DRW, Bruchfeld AN, Harper L, et al. Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis. J Am Soc Nephrol. 2017 Sep;28(9): 2756-2767. doi: 10.1681/ASN.2016111179. Epub 2017 Apr 11.Metzler C, Miehle N, Manger K, et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford). 2007 Jul;46(7):1087-91. Epub 2007 May 22.Metzler C, Miehle N, Manger K, et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford). 2007 Jul;46(7):1087-91. Epub 2007 May 22.Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014 Nov 6;371(19):1771-80. doi: 10.1056/NEJMoa1404231.Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014 Nov 6;371(19):1771-80. doi: 10.1056/NEJMoa1404231.Terrier B, Pagnoux C, Perrodeau E, et al. Long-term efficacy of remission-maintenance regimens for ANCA-associated vas-culitides. Ann Rheum Dis 2018 Aug;77(8): 1150-1156. doi: 10.1136/annrheumdis-2017-21Terrier B, Pagnoux C, Perrodeau E, et al. Long-term efficacy of remission-maintenance regimens for ANCA-associated vas-culitides. Ann Rheum Dis 2018 Aug;77(8): 1150-1156. doi: 10.1136/annrheumdis-2017-21Springer J, Nutter B, Langford CA, et al. Granulomatosis with polyangiitis (Wegener's): impact of maintenance therapy duration. Medicine (Baltimore). 2014 Mar;93(2):82-90. doi: 10.1097/MD.0000000000000020Springer J, Nutter B, Langford CA, et al. Granulomatosis with polyangiitis (Wegener's): impact of maintenance therapy duration. Medicine (Baltimore). 2014 Mar;93(2):82-90. doi: 10.1097/MD.0000000000000020

The authors declare that there are no conflicts of interest present.